Optimization of loop diuretic therapy in chronic heart failure and chronic kidney disease


Cite item

Full Text

Abstract

Association of chronic heart failure and chronic kidney disease is characterized with extremely unfavorable prognosis. Treatment in oedema in this patients can be more effective with torasemid - a loop diuretic with partial aldosterone antagonist activity

References

  1. Bleich M., Greger R. Mechanism of action of diuretics. Kidney Int. 1997;51(Suppl. 59):S11-S15.
  2. Struthers A.D. Impact of aldosterone on vascular pathophysiology. Congest. Heart Fail. 2002;8:18-22.
  3. Ezekowitz J.A., McAlister F.A. Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur. Heart J. 2009;30(4):469-477.
  4. Boesken W.H., Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin. Nephrol. 1997;48(1):22-28.
  5. Fliser D., Schroter M., Neubeck M., et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int. 1994;46(2):482-88.
  6. Gehr T.W., Rudy D.W., Matzke G.R., et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin. Pharmacol. Ther. 1994;56(1):31-38.
  7. Whelton A., Smith W.B., Wallin J.D., et al. Long-term treatment with oral torsemide and its effect on body weight and fluid balance in patients with chronic renal insufficiency. Am. J. Ther. 1996;3(11):743-49.
  8. Cosin J., Diez J., TORIC Investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002;4(4):507-13.
  9. Franse L.V., Pahor M., Di Bari M., et al. Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000;35:1025-30.
  10. Knauf H., Mutschler E., Velazquez H., et al. Torasemide significantly reduces thiazide-induced potassium and magnesium loss despite supra-additive natriuresis. Eur J. Clin Pharmacol. 2009;65(5):465-72.
  11. Goodfriend T.L., Ball D.L., Oelkers W., et al. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63(3):PL45-PL50.
  12. Yamato M., Sasaki T., Honda M., et al. Effects of torasemide on left ventricular function and neurohumoral factors in patients with chronic heart failure. Circ. J. 2003;67:384-90.
  13. Lopez B., Querejeta R., Gonzalez A., et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J. Am. Coll. Cardiol. 2004;43(11):2028-35.
  14. Lopez B., Gonzalez A., Beaumont J., et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J. Am. Coll. Cardiol. 2007;50(9):859-67.
  15. Veeraveedu P.T., Watanabe K., Ma M., et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2007;23:143-48.
  16. Veeraveedu P.T., Watanabe K., Ma M., et al. Comparative effects of torasemide and furosemide in rats with heart failure. Biochem. Pharmacol. 2008;75:649-59.
  17. Lopez B., Gonzalez A., Hermida N., et al. Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int. 2008;(111 Suppl.):S19-S23.
  18. Senzaki H., Kamiyama M., Masutani S., et al. Efficacy and safety of torasemide in children with heart failure. Arch. Dis Child. 2008;93(9):768-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies